氨溴索治疗新型冠状病毒肺炎的临床效果分析

doi:10.19871/j.cnki.xfcrbzz.2022.03.006

新发传染病电子杂志 ›› 2022, Vol. 7 ›› Issue (3): 27-31.doi: 10.19871/j.cnki.xfcrbzz.2022.03.006

氨溴索治疗新型冠状病毒肺炎的临床效果分析

李力¹, 张鑫², 戴慕巍³, 郑欢伟⁴, 康海燕⁴, 许怡⁵, 胡倩⁴, 杨莉⁵, 高会霞⁵, 王瑜玲⁶, 江平⁶, 戴二黑⁵

1. 石家庄市第五医院重症医学科,石家庄 050021;
2. 石家庄市第五医院结核科,石家庄 050021;
3. 河北医科大学第四医院,河北省肿瘤医院骨科,石家庄 050019;
4. 石家庄市第五医院感染科,石家庄 050021;
5. 石家庄市第五医院检验科,石家庄 050021;
6. 石家庄市第五医院内科,石家庄 050021

收稿日期:2022-02-24 出版日期:2022-07-31 发布日期:2022-09-08
通讯作者: 戴二黑,Email：daieh2008@126.com;郑欢伟,Email：13323119317@163.com
基金资助:
1.2020年度河北省科技计划民生科技专项(20277734D); 2.石家庄市重点研发计划项目（防治新型冠状病毒感染专项）（201460513A-1,201460513A-4）; 3.石家庄市科学技术研究与发展计划（211200443）

Analysis of the clinical effect of ambroxol hydrochloride on the treatment of COVID-19

Li Li¹, Zhang Xin², Dai Muwei³, Zheng Huanwei⁴, Kang Haiyan⁴, Xu Yi⁵, Hu Qian⁴, Yang Li⁵, Gao Huixia⁵, Wang Yuling⁶, Jiang Ping⁶, Dai Erhei⁵

1. Intensive care unit, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China;
2. Department of Tuberculosis, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China;
3. Department of Orthopaedic, The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang 050019, China;
4. Department of Infectious Disease, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China;
5. Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China;
6. Department of Internal Medicine, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China

Received:2022-02-24 Online:2022-07-31 Published:2022-09-08

摘要/Abstract

摘要： 目的观察盐酸氨溴索治疗新型冠状病毒肺炎的临床疗效和安全性。方法选取2020年1–6月在石家庄市第五医院住院的68例新型冠状病毒肺炎患者,随机分为对照组和观察组,每组34例。观察组和对照组患者均给予α干扰素500万U,雾化,2次/d;阿比多尔0.2g,口服,3次/d,疗程10d。观察组患者在接受常规治疗的基础上予盐酸氨溴索葡萄糖注射液（30mg,2次/d,静脉滴注）治疗,疗程2周。比较两组患者临床疗效、血清炎性指标变化及药物不良反应发生率。结果观察组治疗总有效率（85.3%）显著高于对照组（70.6%）,差异有统计学意义(P<0.05)。观察组临床症状改善时间、肺部影像学改善时间以及住院时间均短于对照组,但差异均无统计学意义（P>0.05）。观察组治疗后的降钙素原（PCT）和C反应蛋白（CRP）水平较治疗前均明显降低（P<0.05）,白细胞计数和淋巴细胞计数较治疗前均明显升高（P<0.05）;对照组治疗后CRP水平较治疗前明显降低（P<0.05）,白细胞计数和淋巴细胞计数较治疗前均明显升高（P<0.05）,但PCT水平治疗前、后无明显差异（P>0.05）。观察组和对照组患者治疗期间均无不良反应发生。结论新型冠状病毒肺炎患者应用盐酸氨溴索治疗有助于促进其临床症状缓解及肺部病灶吸收并可减低炎症反应。

关键词: 新型冠状病毒, 肺炎, 氨溴索, 临床效果, C反应蛋白, 降钙素原

Abstract: Objective To observe the clinical efficacy and safety of ambroxol hydrochloride on the treatment of Coronavirus disease 2019(COVID-19). Method A total of 68 patients with COVID-19 hospitalized in the Fifth Hospital of Shijiazhuang from January to June 2020 were selected and divided into control group and observation group, with 34 cases in each group. Both observation group and control group were given interferon-α5 million U, atomized, twice a day; arbidol 0.2g, orally, 3 times/d, for 10d. Observation group was treated with ambroxol hydrochloride glucose injection (30 mg, twice a day, iv drip) on the basis of conventional treatment for 2 weeks. The clinical efficacy, changes in serum inflammatory indexes and the incidence of adverse drug reactions were compared between the two groups. Result The total effective rate of observation group (85.3%) was significantly higher than that in the control group (70.6%) (P<0.05). The clinical symptoms improvement time, pulmonary imaging improvement time and hospitalization time in the observation group were shorter than those in the control group, but the differences were not statistically significant (P>0.05). The levels of serum PCT and CRP in the observation group were significantly lower after treatment than before (P<0.05), leukocyte count and lymphocyte count were significantly higher than those before treatment (P<0.05). In the control group the CRP level after treatment was significantly lower than that before treatment (P<0.05), the leukocyte count and lymphocyte count were significantly higher than those before treatment (P<0.05), but there was no significant difference in PCT level before and after treatment (P>0.05). There was no adverse reaction in the observation group and the control group during the treatment period. Conclusion Ambroxol hydrochloride treatment for COVID-19 patients can promote the remission of clinical symptoms and absorption of pulmonary lesions, and reduce inflammatory response, which is worthy of popularization and application.

Key words: Severe acute respiratory syndrome coronavirus 2, Pneumonia, Ambroxol, Clinical effect, C-reactive protein, Procalcitonin

李力, 张鑫, 戴慕巍, 郑欢伟, 康海燕, 许怡, 胡倩, 杨莉, 高会霞, 王瑜玲, 江平, 戴二黑. 氨溴索治疗新型冠状病毒肺炎的临床效果分析[J]. 新发传染病电子杂志, 2022, 7(3): 27-31.

Li Li, Zhang Xin, Dai Muwei, Zheng Huanwei, Kang Haiyan, Xu Yi, Hu Qian, Yang Li, Gao Huixia, Wang Yuling, Jiang Ping, Dai Erhei. Analysis of the clinical effect of ambroxol hydrochloride on the treatment of COVID-19[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(3): 27-31.

参考文献

[1] 中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].[2020-02-20]. http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm.
[2] ZHU N, ZHANG D, WANG W, et al.A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
[3] CHAN JFW, KOK KH, ZHU Z, et al.Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infect, 2020, 9(1): 221-236.
[4] GORBALENYA AE, BAKER SC, BARIC RS, et al.Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying SARS-CoV-2 and naming it SARS-CoV-2[J]. Nat Microbiol, 2020, 5(4): 536-544.
[5] 中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组. 新型冠状病毒肺炎流行病学特征分析[J] . 中华流行病学杂志, 2020,41(2): 145-151.
[6] PARUMS DV.EDITORIAL: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients[J]. Med Sci Monit, 2022, 28: e935952.
[7] 郭津含,陈建林,葛岚岚,等. 金银花对轻型新型冠状病毒肺炎治疗的药理价值[J/CD]. 新发传染病电子杂志, 2021, 6(3):181-188.
[8] HULL JD, LYON RA.In vitro pharmacology of ambroxol: Potential serotonergic sites of action[J]. Life Sci, 2018, 197: 67-72.
[9] 田卓民, 杜韵泽, 何慧英, 等. 沐舒坦治疗康复期 SARS 肺间质病变1例[J]. 临床肺科杂志, 2004, 9(5): 556-557.
[10] 李敏, 王进. 氨溴索治疗2019新型冠状病毒肺炎的研究现状[J]. 中国临床药理学杂志, 2020, 36(9): 1157-1159.
[11] MALERBA M, RAGNOLI B.Ambroxol in the 21st century: pharmacological and clinical update[J]. Expert Opin Drug Metab Toxicol, 2008, 4(8): 1119-1129.
[12] PALEARI D, ROSSI GA, NICOLINI G, et al.Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood[J]. Expert Opin Drug Discov, 2011, 6(11): 1203-1214.
[13] DEPFENHART M, VILLIERS D, LEMPERLE G, et al.Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?[J]. Intern Emerg Med, 2020, 15(5): 801-812.
[14] ALKOTAJI M.Azithromycin and ambroxol as potential pharmacotherapy for SARS-COV-2[J]. Int J Antimicrob Agents, 2020, 56(6):10619
[15] CARPINTEIRO A, GRIPP B, HOFFMANN M, et al.Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells[J]. J Biol Chem, 2021, 296: 100701.
[16] 李菁, 朱凌云. 南京市79例普通型新型冠状病毒肺炎患者的用药情况分析及用药合理性评价[J]. 山东医药, 2020, 60(15):22-26.
[17] CHEN N, ZHOU M, DONG X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513
[18] XU Z, SHI L, WANG Y, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422.
[19] HUANG C, WANG Y, LI X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[20] CHAN JFW, YUAN S, KOK KH, et al.A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523.
[21] XU Z, SHI L, WANG Y, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422.
[22] Tan L, Wang Q, Zhang D, et al.Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study[J]. Signal Transduct Target Ther, 2020, 5(1):33.
[23] 陈国华, 潘志伟, 白珺. 盐酸氨溴索对婴幼儿重症肺炎潮气呼吸肺功能的影响[J]. 泰山医学院学报, 2018, 39(3):324-325.
[24] 唐劲松, 宣春, 林景涛, 等. C-反应蛋白、白介素-6及降钙素原检测在新冠肺炎中的临床意义[J]. 实用医学杂志, 2020, 36(7):839-841.
[25] 郭蕊, 陈媛媛, 于智君, 等. 新型冠状病毒肺炎不同分型患者血清淋巴细胞计数、CRP、PCT、细胞因子水平变化及临床意义[J].海南医学, 2021, 32(24):3155-3158.

氨溴索治疗新型冠状病毒肺炎的临床效果分析

Analysis of the clinical effect of ambroxol hydrochloride on the treatment of COVID-19

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张影, 李晓鹤, 陈凤, 袁静. 新型冠状病毒德尔塔和奥密克戎变异株感染患者的临床特征分析[J]. 新发传染病电子杂志, 2022, 7(3): 22-26.
[2]	刘星, 吴威, 张晓明, 李强, 权冬梅, 张朕, 戴越, 张麟格, 宋冠男, 李欣悦, 朱一丹, 王岩. 非酒精性脂肪性肝病及原发性肝细胞癌患者接种新型冠状病毒灭活疫苗的安全性及免疫原性[J]. 新发传染病电子杂志, 2022, 7(3): 50-54.
[3]	袁静, 谭晓华, 王福祥, 王绿化, 卢洪洲. 恶性肿瘤患者新冠病毒疫苗接种的专家意见[J]. 新发传染病电子杂志, 2022, 7(2): 1-5.
[4]	刘文浩, 杨金荣, 陈一鑫, 周昀, 李银凤, 云永兴, 杨根东, 黄华. 新型冠状病毒奥密克戎变异株感染：普通型与无症状/轻型的临床特征比较分析及胸部CT表现[J]. 新发传染病电子杂志, 2022, 7(2): 6-10.
[5]	刘栋, 王帅迪, 冯明男, 黄顺星, 李硕, 杜霄鹏, 刘亚欧, 丁金立. 新型冠状病毒肺炎防控常态化情况下隔离区方舱CT的临床应用探讨[J]. 新发传染病电子杂志, 2022, 7(2): 11-14.
[6]	蒋学美, 宋艳, 陈艳, 何利, 邵蔚. 新型冠状病毒肺炎疫情常态化下消毒供应中心的防控策略[J]. 新发传染病电子杂志, 2022, 7(2): 15-18.
[7]	牛翊霖, 张纯, 曹雯煜, 刘旭玲, 吴清华, 刘滢芳, 张宝, 赵卫. 年龄因素对新型冠状病毒易感性的影响[J]. 新发传染病电子杂志, 2022, 7(2): 19-24.
[8]	江苏省研究型医院学会感染与炎症放射学专业委员会, 江苏省放射诊断专业质量控制中心, 江苏省医学会放射学分会感染病学组. 江苏省新型冠状病毒肺炎影像学检查、诊断及防控规范专家共识（2022第二版）[J]. 新发传染病电子杂志, 2022, 7(2): 79-88.
[9]	廖康生, 卢洪洲. 新型冠状病毒奥密克戎变异株的研究进展：对其科学防控措施的启示[J]. 新发传染病电子杂志, 2022, 7(1): 1-5.
[10]	于埼, 宋艳, 刘思聪, 王梦梦, 张爱玲. 非感染科抗疫支援护士医院感染防控知信行的调查分析[J]. 新发传染病电子杂志, 2022, 7(1): 60-65.
[11]	芦鸿曦, 刘刚, 陈歆. 世界卫生组织关注的新型冠状病毒变异株病毒学特征分析[J]. 新发传染病电子杂志, 2022, 7(1): 88-91.
[12]	吴伟刚, 杨智, 欧鹏程, 曾芙蓉, 吕小青, 王佳露, 郭建伟, 吴诗品, 杨桂林. 及时更新的诊疗方案对新型冠状病毒肺炎疫情防控的临床价值[J]. 新发传染病电子杂志, 2022, 7(1): 100-103.
[13]	吴琰, 魏会平, 曹欣, 赵慧, 陆丹, 王卉. 儿童下呼吸道肺炎支原体感染流行特点分析[J]. 新发传染病电子杂志, 2021, 6(4): 336-338.
[14]	詹香明, 卢洪洲. 新型冠状病毒肺炎对全球HIV感染者影响的研究进展[J]. 新发传染病电子杂志, 2021, 6(4): 356-360.
[15]	卢春容, 房宏霞, 陆普选, 季乐财. WHO 2021年全球结核病报告：全球与中国关键数据分析[J]. 新发传染病电子杂志, 2021, 6(4): 368-372.